The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers.
The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers.
复制标题
DOI：
10.3390/life13061310
复制
发表时间：
2023-06-01
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
干扰素（ifn）在各种皮肤癌，特别是鳞状细胞癌（SCC）、基底细胞癌（BCC）和黑色素瘤中具有治疗潜力。I型干扰素在皮肤癌中发挥抗肿瘤作用的确切机制仍在研究中。然而，病灶内I型IFN可以作为选择性患者手术的替代方案，并且高剂量全身IFN治疗已被证明对可手术的高风险或转移性黑色素瘤患者有希望。尽管ifn在皮肤癌治疗中具有治疗潜力，但其毒性特征往往阻碍了治疗的完成和进一步扩大其临床应用。I型和III型ifn使用相同的Janus激酶（JAKs）进行信号转导，这是基于这种共享的信号通路，在细胞表面受体启动介导细胞核中靶基因激活的途径。由于选择性肿瘤靶向和产生先天和适应性免疫反应的能力，我们得出结论，与选择性肿瘤靶向治疗相比，III型ifn具有最小的副作用。虽然IFN-λ是一种III型IFN，显示出单独或与另一种IFN联合的治疗潜力，但需要进一步的研究来探索IFN-λ在皮肤癌中的治疗潜力及其潜在的生理作用和作用机制。在这篇综述中，我们评估了与现有治疗方法相比，III型IFN治疗皮肤癌是否具有最小的副作用。
Interferons (IFNs) have demonstrated therapeutic potential in various skin cancers, specifically squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and melanoma. The precise mechanism through which type I IFNs exert their antitumor effects in skin cancers is still being studied. However, intralesional type I IFN can be used as an alternative to surgery for select patient populations, and high-dose systemic IFN therapy has been shown to be promising in patients with operable high-risk or metastatic melanoma. Despite the therapeutic potential of IFNs in skin cancer treatment, the toxicity profile often prevents the completion of treatment and further expansion of its clinical application. Type I and III IFNs use the same Janus Kinases (JAKs) for signal transduction, which are pathways initiated at a cell surface receptor that mediates the activation of target genes in the nucleus, based on this shared signaling pathway. Due to selective tumor targeting and the ability to generate both innate and adaptive immune responses, we concluded that type III IFNs have minimal side effects compared with established treatments due to selective tumor targeting. While IFN-λ, a type III IFN, shows therapeutic potential as stand-alone or in combination with another IFN, further studies need to be conducted to explore the therapeutic potential of IFN-λ in skin cancer and the underlying physiological roles and mechanisms of action. In this review, we evaluate whether treatment of skin cancer with type III IFN will have minimal side effects compared with established treatments.
登录
查看更多内容
DOI：
10.1016/0190-9622(90)70276-n
发表时间：
1990-10-01
影响因子：
13.8
作者：
CORNELL, RC;GREENWAY, HT;PEETS, EA
通讯作者：
PEETS, EA
影响因子：
3.1
作者：
LEISTWELSH, P;BJORNSON, AB
通讯作者：
BJORNSON, AB
影响因子：
--
作者：
Tagawa M;Kawamura K;Li Q;Tada Y;Hiroshima K;Shimada H
通讯作者：
Shimada H
影响因子：
5.8
作者：
Li, Meng;Rao, Chunming;Wang, Junzhi
通讯作者：
Wang, Junzhi
影响因子：
5.2
作者：
Arico, Eleonora;Castiello, Luciano;Belardelli, Filippo
通讯作者：
Belardelli, Filippo